Green Circle Decarbonize Technology Limited Overview
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Employees (headcount) | — | 4 | 3 |
Note: FY2025 figure from IPOScoop profile; FY2026 figure from Renaissance Capital/MoneyDJ/FXEmpire.
Green Circle Decarbonize Technology is a Hong Kong–based micro-cap engineering and materials company that commercializes proprietary phase change material (PCM) thermal energy storage (TES) technology developed by its founder over three decades. Its core assets are more than 20 PCM formulations spanning -86°C to +600°C, HDPE-encapsulated "BocaPCM-TES Panels," and an integrated "Ultra-High Efficiency Boca Hybrid Power Chiller Plant" with self-developed automatic controls that shift chiller load to off-peak tariff periods. The flagship reference installation at HAECO's Hong Kong International Airport headquarters is claimed to cut electricity use by at least 40% and running costs by roughly 50–70%. The business is tiny (FY2026 revenue HK$25.1M / ~US$3.2M), loss-making (FY2026 net loss HK$13.1M), and extremely concentrated (two customers ≈95% of revenue). Since its January 2026 IPO it has pivoted to an asset-light manufacturing model via SANVO Fine Chemicals, while financing itself through a highly dilutive note, warrant and equity-line package.
Company's own description (FY2026 20-F)
The company describes itself as a provider of advanced energy-saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. Its stated mission is to preserve the world through decarbonization technologies. By applying material science and nanotechnology, it developed PCM that temporarily stores surplus thermal energy for later use, bridging the timing gap between energy availability and demand. It encapsulates PCM in custom HDPE containers (BocaPCM-TES Panels), integrates these into a PCM-TES system, and deploys that system within central air-conditioning plants marketed as the Ultra-High Efficiency Boca Hybrid Power Chiller Plant, operated by a self-developed fully automatic control system.
Independent characterization
In substance, GCDT is a project-based building-services energy-efficiency contractor with an embedded specialty-materials IP core. Revenue is not driven by product volume; it is driven by a handful of large, lumpy engineering contracts (lump-sum chiller-plant and MVAC installations) plus one long-running energy performance contract (EPC/"PBC model") at HAECO. The company manufactures PCM in-house in small quantities but buys all heavy plant (chillers, refrigeration units, cooling towers, pumps) and subcontracts installation. It is therefore closer to a niche ESCO (energy service company) and design-build integrator than to a materials manufacturer. Gross margins have compressed from 54% (FY2022) to 17% (FY2026) as revenue mix has shifted from performance-based savings income toward pass-through construction work.
Revenue model
| Revenue stream | Description | Contract form | Margin character |
|---|---|---|---|
| Energy saving service income | Performance-based contracts (PBC): company funds and installs the system, customer pays a share of realized energy savings over the contract term. Principal example: HAECO | Multi-year, performance-linked | Recurring, but capital-intensive up front (debt-funded) |
| Construction service income | Lump-sum fixed-price supply-and-install of BocaPCM-TES systems / chiller plants / MVAC works | One-off project | Low margin; high pass-through of equipment and subcontract cost |
| Consultancy service income | R&D consultancy (e.g., SOAR Equipment Rental project, FY2025) | One-off | Variable |
| Project-related services (stated) | Project management, commissioning, operations & maintenance, remote monitoring | Ancillary | — |
| Product sales (PCM / panels) | Panels sold via agents; future China mass production via SANVO | Product | Not separately reported in reviewed materials |
The mix by product vs. service vs. subscription vs. licensing is not formally disclosed. Based on customer-level disclosure, FY2026 revenue was approximately half performance-contract/service income linked to HAECO and half construction income (Macau hospital and Bayview Garden). There is no material licensing or subscription revenue disclosed.
Value-chain position
| Value-chain stage | GCDT role |
|---|---|
| Raw materials (chemicals, nanomaterials) | Buyer; single German nanomaterial supplier, order-by-order, no long-term contract |
| PCM formulation | In-house (core IP) |
| Panel encapsulation | In-house historically; China mass production outsourced to SANVO from September 2026 |
| Heavy HVAC equipment | Buyer (chillers, cooling towers, pumps from third parties) |
| System design & controls | In-house (automatic control software developed 2015; AI/MPC upgrade in development) |
| Installation | Subcontracted |
| Financing of customer projects | Company-funded via debt/equity under PBC model |
| Distribution outside Hong Kong | Five local agents (Hong Kong, Shanghai, Guangdong, Korea, Dubai) on two-year agreements |
Customer types and end-markets
Customers disclosed to date are institutional/commercial building owners and operators: aviation MRO (HAECO), healthcare (Macau University of Science and Technology Foundation – University Hospital), retail property (Bayview Garden Shopping Centre via LMP International Limited), and equipment rental/industrial (SOAR Equipment Rental Company Limited, consultancy). Targeted end-markets per the prospectus include commercial and public buildings, cold chain/biobank storage (with Gene Company Limited), data-center liquid cooling, and solar-thermal domestic heating.
Strategy
Stated strategy (IPO prospectus / 20-F themes)
-
Substantial reliance on the PBC (performance-based contract) model, with the added aim of helping clients earn carbon credits for sale in carbon markets.
-
Strategic alliances and solicitation with NGOs, green funds and companies with decarbonization targets or high electricity consumption.
-
Continuous innovation: cold chain (GeneHK), data-center liquid cooling, AI/model-predictive control, solar-thermal domestic heating.
-
Expansion of project-related services (project management, commissioning, O&M), including certifying third-party service providers.
-
Arrangement of project financing with banks and financial institutions for customers.
-
Mass production of BocaPCM-TES Panels — originally via an own factory in the PRC; now via SANVO.
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Bayview Garden MVAC/TES contract | Aug 2024 | HK$12.999M lump sum | Largely recognized FY2025–FY2026 |
| Macau hospital chiller plant | Mar 2025 | HK$14.0M lump sum incl. BocaAI Controls | Completed May 2026 |
| IPO and listing | Jan–Feb 2026 | US$11.5M gross | Completed |
| Production capacity plan (factory) | IPO use of proceeds | 46.8% of net proceeds earmarked | Apparently superseded by SANVO outsourcing |
| CFO succession | Apr–Jun 2026 | Leung appointed | Completed |
| July 2026 financing | Jul 2026 | US$10M OID note, 29.1M warrants at US$2.00, US$100M equity line (Target Capital 1) | First tranche funded; further tranches conditional |
| Governance recapitalization | Aug 2026 | 5bn authorized shares; dual class; consolidation | Effective |
| SANVO manufacturing partnership | Sep 2026 | Sole supplier/exclusive manufacturer in PRC; 3-year initial term with automatic 3-year renewals | Framework; formal operational agreements to follow |
| NYSE American compliance | Sep–Oct 2026 | 1-for-6 consolidation | Effective 7 Oct 2026 |
Medium-term targets and guidance
The company has not issued quantitative revenue, margin or profitability guidance. The 20-F contains a qualitative statement that management expects sufficient funds for twelve months.
Products & Services
All products sit within the single energy-saving solutions business.
Product Portfolio
| # | Product / service | Description & key capabilities | Target customer | Launch / version | Pricing model |
|---|---|---|---|---|---|
| 1 | BocaPCM (PCM formulations) | 20+ proprietary PCM types, each with a distinct phase-change temperature and TES capacity; operating range -86°C to +600°C. Flagship +8°C PCM (1992) optimized for chilled-water air conditioning; +58°C PCM for solar-thermal heat storage | HVAC, refrigeration, heating integrators | 1992 onward | — |
| 2 | BocaPCM-TES Panel | Custom HDPE plastic container fully filled with PCM solution; ultrasonic-welded design (2013) to enhance heat transfer. Third-generation encapsulation after steel balls (2003) and first HDPE panels (2007) | HVAC/refrigeration systems; agents | 2007 (HDPE), 2013 (ultrasonic) | Not disclosed; China mass production via SANVO from 2026 |
| 3 | BocaPCM-TES System / tanks | Thermal energy storage system built from panels, installed in tanks within central chilled-water plants; stores surplus cooling when chiller output exceeds load and releases it when load exceeds output; acts as standby capacity on equipment failure | Building owners | — | Lump-sum or PBC |
| 4 | Ultra-High Efficiency Boca Hybrid Power Chiller Plant | Integrated chiller plant combining third-party chillers/cooling towers with BocaPCM-TES and automatic controls; shifts load to off-peak tariff periods via real-time demand peak management; claimed ≥40% electricity reduction and ~50–70% running-cost reduction (HAECO reference); patent applications filed in the US and PRC | Commercial, institutional, airport, hospital buildings | Plant concept in operation at HAECO; latest version 2025–26 (Macau) | Lump-sum (e.g., HK$14.0M Macau) or performance-based |
| 5 | Fully automatic control system / "BocaAI Controls" | Self-developed control software (2015) optimizing chiller COP and charge/discharge scheduling; model predictive control (MPC) / self-learning AI upgrade in development | Bundled with plant | 2015; AI version in development (BocaAI named in Macau scope) | Bundled |
| 6 | Energy performance contracting (PBC model) | Company funds equipment and installation; customer pays a portion of realized energy savings over the term; company also positions customers to earn carbon credits | Large-load building owners | — | Savings share |
| 7 | Construction / MVAC installation services | Supply and installation of complete mechanical ventilation and air conditioning (MVAC) including BocaPCM-TES (e.g., Bayview Garden, ~50,000 sq ft GFA) | Property owners, contractors | Aug 2024 contract | Lump-sum fixed price (HK$12.999M) |
| 8 | Consultancy (R&D services) | R&D consultation (SOAR Project) | Industrial clients | FY2025 | Fee |
| 9 | Project management, commissioning, O&M | End-to-end project management; performance commissioning; remote monitoring and periodic onsite maintenance | Installed-base customers | Ongoing | — |
| 10 | Cold chain / biobank products (development) | With Gene Company Limited (GeneHK): ultra-low-temperature transport boxes and freezer backup systems; exclusive supply in Mainland China, HK, Macau, Taiwan for research, medical, diagnostic, pharma, life sciences, biotech | Labs, biobanks, pharma | Development | Product development & supply agreement |
| 11 | Dual-circuit liquid cooling for data centers (development) | Combines refrigeration-based basic cooling with direct/immersion liquid cooling to reduce operating cost and noise; negotiations with a major Hong Kong bank disclosed in prospectus | Data centers | Development | — |
| 12 | Domestic heating system (development) | +58°C PCM combined with vacuum-tube solar collectors for underfloor/domestic heating; company has stated intent to acquire a vacuum-tube collector manufacturer (no target named) | Residential | Development | — |
“—” = not publicly disclosed.
Financial Narrative
All figures HKD thousand unless stated; source F-1 (FY2022–FY2023, audited by BF Borgers) and FY2026 20-F (FY2024–FY2026, audited by ZH CPA). Ratios derived by the analyst.
Per-share data
Notes: The pre-IPO share count was 10,000,000 (per prospectus). FY2022 share count is uncertain given 2022 reorganization subscriptions. Interim cross-check: H1 FY2026 loss per share HK$0.23 on HK$2.3M net loss (consistent with 10M shares). Basic and diluted are identical (loss-making; anti-dilutive instruments).
Margins and growth
Revenue CAGR FY2022–FY2026 (derived): (25,051 / 6,868)^(1/4) − 1 ≈ 38.2%. FY2024–FY2026 two-year CAGR ≈ 118.7%.
Interim (half-year) results
Source: F-1 (2024) for H1 FY2023/FY2024; 6-K furnished 6 Feb 2026 (via StockTitan summary) for H1 FY2025/FY2026 (rounded to HK$0.1M).
Income statement commentary
Scale and volatility. Revenue is a function of one or two contracts per year. FY2024 (HK$5.2M) was entirely HAECO savings income; FY2025 (HK$16.6M) added the Bayview Garden construction contract (HK$8.5M recognized) and the SOAR consultancy (HK$3.0M); FY2026 (HK$25.1M) was driven by the Macau hospital project (≈HK$11.7M recognized) and a step-up in HAECO income. Absent new lump-sum awards, FY2027 revenue will fall back toward recurring HAECO income because the Macau project completed in May 2026 and Bayview Garden is substantially recognized.
Margin compression is structural, not cyclical. Gross margin fell every year from 54.0% (FY2022) to 17.3% (FY2026). The drivers are mix: performance-contract savings income (high gross margin once the plant is depreciated) has been diluted by construction contracts in which chillers, cooling towers and subcontracted labor are passed through at thin markups. The business is growing revenue by becoming more of a contractor.
Operating losses persist at every revenue level. Operating loss widened to HK$6.8M in FY2026 despite record gross profit, reflecting public-company costs (listing, legal, audit, D&O insurance) layered on a very small cost base.
Below-the-line charges tripled in FY2026. The gap between operating loss and pre-tax loss rose from ~HK$2.1–2.6M (FY2022–FY2025) to HK$6.3M in FY2026. This should be verified in the 20-F notes.
No tax shield. Small tax credits in FY2022–FY2023 ceased; no deferred tax asset recognition is evident from reported figures.
Balance sheet
The latest verified balance sheet is the pre-IPO interim at 30 September 2025.
Source: 6-K interim report (StockTitan summary). Seeking Alpha shows "Q4 2025" total assets US$3.46M and total liabilities US$6.45M, consistent with these HKD figures at HK$7.80.
Borrowings at 31 March 2026 (partial, from 20-F XBRL):
Aggregator data (flagged): Benzinga displays TTM operating cash flow -15.52M, investing -8.58M (capex), financing +59.03M, net change in cash +34.92M, total debt 29.79M and total cash 258.3K, labelled "$". The cash-flow figures are internally consistent and appear to be FY2026 HKD amounts mislabelled as USD; the "total cash 258.3K" figure is inconsistent with a +HK$34.9M net cash increase and likely relates to a different period or entity-level figure. These should not be relied upon without the 20-F statements.
Cash flow (verified items only)
capex -8580; FCF -24100; financing +59030.
Ratios
Commentary: Most ratios are not meaningful or not computable from verified data. Equity was negative pre-IPO (HK$-23.3M at 30 Sep 2025), so ROE and debt/equity were undefined; EBITDA is negative or undisclosed, so leverage and coverage ratios are not meaningful. On an annualized H1 FY2026 basis, asset turnover was roughly 0.9x (HK$23.6M annualized revenue / HK$26.9M assets) — indicative only. The 20-F states management believes it has sufficient funds for twelve months from the report date, a materially more benign statement than the explicit going-concern uncertainty disclosed at 30 September 2025 and 31 March 2025; that improvement is attributable to IPO proceeds and the July 2026 financing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Role |
|---|---|---|---|
Green Circle Decarbonize Technology Limited | Cayman Islands | Listed holdco | Holding company; no substantive operations |
Boca International Limited | Hong Kong | 100% | Sole operating subsidiary (R&D, PCM production, projects) |
Joyful Star Limited | (Chan vehicle) | Shareholder | Holds 5,280,000 pre-consolidation shares (now Class B) |
Green Circle Limited | (Chan vehicle) | Shareholder | Holds 1,080,000 pre-consolidation shares (now Class B) |
Customer (HKD K, derived = % × total revenue)
| Customer (HKD K, derived = % × total revenue) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
HAECO (energy saving service; HKIA chiller plant) | 5,236 | 5,079 | 12,142 |
Macau Univ. of Science & Technology Fdn – University Hospital (construction) | 0 | 0 | 11,747 |
LMP International – Bayview Garden (construction) | 0 | 8,496 | 1,162 |
SOAR Equipment Rental (consultancy) | 0 | 3,000 | 0 |
Total revenue | 5,236 | 16,575 | 25,051 |
Customer share of revenue (%)
| Customer share of revenue (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
HAECO | 100.00 | 30.64 | 48.47 |
Macau University Hospital | 0.00 | 0.00 | 46.89 |
LMP International | 0.00 | 51.26 | 4.64 |
SOAR Equipment Rental | 0.00 | 18.10 | 0.00 |
Income Statement
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 6,868 | 6,587 | 5,236 | 16,575 | 25,051 |
Cost of revenue | -3,159 | -4,111 | -3,791 | -12,824 | -20,706 |
Gross profit (derived) | 3,709 | 2,475 | 1,445 | 3,751 | 4,345 |
Operating loss | -322 | -2,942 | -5,657 | -3,917 | -6,834 |
Non-operating items incl. finance costs (derived: LBT − operating loss) | -2,560 | -2,051 | -2,265 | -2,066 | -6,280 |
Loss before tax | -2,882 | -4,993 | -7,922 | -5,982 | -13,113 |
Income tax credit (derived) | 130 | 506 | 0 | 0 | 0 |
Net loss (loss & total comprehensive loss) | -2,752 | -4,487 | -7,922 | -5,982 | -13,113 |
Dividends per share | 0 | 0 | 0 | 0 | 0 |
Per-Share Data
| Metric (HKD) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Loss per share, derived (net loss ÷ 10,000,000 pre-IPO shares) | -0.45 | -0.79 | -0.60 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY | — | -4.1 | -20.5 | 216.5 | 51.1 |
Gross margin | 54.0 | 37.6 | 27.6 | 22.6 | 17.3 |
Operating margin | -4.7 | -44.7 | -108.0 | -23.6 | -27.3 |
Net margin | -40.1 | -68.1 | -151.3 | -36.1 | -52.3 |
Financial Analysis
| Metric | FY2026 (USD K) |
|---|---|
Revenue | 3,212 |
Gross profit | 557 |
Operating loss | -876 |
Net loss | -1,681 |
Income Statement (Half-Yearly)
| Metric (HKD K) | H1 FY2023 (6m to 30 Sep 2022) | H1 FY2024 (6m to 30 Sep 2023) | H1 FY2025 (6m to 30 Sep 2024) | H1 FY2026 (6m to 30 Sep 2025) |
|---|---|---|---|---|
Revenue | 2,709 | 2,107 | 4,800 | 11,800 |
Gross profit | — | — | — | 2,800 |
Operating loss | -2,087 | -2,152 | -1,900 | -1,000 |
Net loss | -2,765 | -2,929 | -2,800 | -2,300 |
Balance Sheet Item Details
| Balance sheet item (HKD K) | 30 Sep 2025 |
|---|---|
Total assets | 26,900 |
Total liabilities | 50,200 |
Shareholders' equity (deficit) | -23,300 |
Cash and equivalents | 1,100 |
Bank and other borrowings | 31,800 |
Net debt (derived: borrowings − cash) | 30,700 |
Working capital | -39,200 |
Goodwill & intangibles | 0 |
Financial Analysis — IPO gross proceeds
| Item | Amount | Date |
|---|---|---|
IPO gross proceeds | US$10.0M (net ≈ US$8.57M) | 14 Jan 2026 |
Over-allotment gross proceeds | US$1.5M | 12 Feb 2026 |
Founders' loan settled | HK$4.6M outstanding balance settled post-IPO | After 14 Jan 2026 |
Loan 2 principal repaid | HK$6,618,280 | Jan–Mar 2026 |
Loan 8 (bank) drawn | HK$2,500,000 at 6.25% | 14 Jan 2026 |
July 2026 note first installment | US$2.0M cash received (US$10.0M face note issued; OID 20%) | 24 Jul 2026 |
Equity purchase agreement initial sale | US$1.0M (676,205 shares + 1,143,962 pre-funded warrants) | 24 Jul 2026 |
Loan Details
| Loan | Principal (HKD) | Rate | Inception | Maturity / security |
|---|---|---|---|---|
Loan 5 (other borrowing) | 990,000 | 5.00% | 4 Sep 2018 | On demand; unsecured |
Loan 6 (bank) | 1,004,400 | — | 7 Sep 2021 | — |
Loan 7 (bank) | 3,000,000 | — | 21 May 2025 | — |
Loan 8 (bank) | 2,500,000 | 6.25% | 14 Jan 2026 | — |
Loans 1–4 | — | — | — | Loan 2 had a 12-year repayment term; HK$6.62M repaid in Q4 FY2026 |
Cash flow item (HKD K)
| Cash flow item (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Region revenue (HKD K, derived)
| Region revenue (HKD K, derived) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hong Kong | 5,236 | 16,575 | 13,304 |
Macau | 0 | 0 | 11,747 |
Mainland China | 0 | 0 | 0 |
Rest of world | 0 | 0 | 0 |
Region growth YoY (%)
| Region growth YoY (%) | FY2025 | FY2026 |
|---|---|---|
Hong Kong | 216.5 | -19.7 |
Share Price History
| Date | Price (USD) | Note |
|---|---|---|
12 Jan 2026 | 4.00 | IPO price |
13 Jan 2026 | ~4.21 | First-day return +5.3% |
Jan–Feb 2026 | 5.85 | 52-week high |
9 Feb 2026 | 4.30 | Market cap ~US$53.7M |
27 Feb 2026 | 1.92 | -23.2% day |
23 Mar 2026 | 0.87 | — |
6 Apr 2026 | 1.24 | — |
26 May 2026 | 0.75 | — |
31 Aug 2026 | 0.41 | Market cap ~US$7.9M |
9 Sep 2026 | 0.64 | Post-SANVO spike then -29.9% day |
Early Oct 2026 | 0.37–0.40 | Pre-consolidation; market cap ~US$4.8–5.4M |
52-week low | 0.33 | — |
Return metric (%) | Value | — |
Since IPO (to ~US$0.37 pre-split) | -90.7 | — |
1-year | n/a (listed Jan 2026) | — |
Shares outstanding (thousand)
| Shares outstanding (thousand) | FY2025 | FY2026 | Aug 2026 | Post-consolidation (derived) |
|---|---|---|---|---|
Total ordinary shares | 10,000 | 12,875 | 13,551 | 2,259 |
Class B shares | 0 | 0 | 6,360 | 1,060 |
Capital Instruments
| Instrument | Quantity / size | Key terms |
|---|---|---|
July 2026 Warrants | Up to 29,122,679 shares | Initial exercise US$2.00; full-ratchet anti-dilution to floor; six-monthly price resets; automatic cashless exercise at expiry; Black-Scholes repurchase right on fundamental transactions |
July 2026 Pre-Funded Warrants | 1,143,962 shares | Exercise US$0.001 |
July 2026 Note | US$10.0M face; US$8.0M subscription in 3 installments (US$2.0M paid; US$0.5M on resale registration filing; US$5.5M on effectiveness) | 20% OID; no interest until maturity 16 Jan 2027; convertible at greater of US$0.1099 floor and 80% of lowest close in prior 5 trading days; prepayable at 110%; holder may require up to 50% of new raise proceeds for repayment |
Equity Purchase Agreement | Up to US$100.0M | Investor purchases at prices set by agreement; plus up to US$2.0M commitment shares |
Underwriters' Warrants | 62,500 shares each to representative and co-manager | Exercise US$4.00; exercisable 30 Sep 2026 – 30 Sep 2029 |
Valuation Multiples
| Multiple | GCDT | Basis |
|---|---|---|
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative/undisclosed EBITDA |
P/S | ~1.4–2.1x | Aggregator (Benzinga) range Aug–Sep 2026; ~1.6x derived from ~US$5M market cap / US$3.2M FY2026 revenue |
P/B | ~1.1–1.8x (aggregator) | Book value/share US$0.36 per Benzinga |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus / price targets | None (no coverage; Yahoo shows no 1-year target) |
Dividend history / policy | Never paid; no intention to pay in foreseeable future; HK subsidiary has accumulated deficit preventing distributions |
Buyback authorizations | None (other than technical repurchases for Class B swap) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Short interest | ~2.5% (Benzinga) |
Analyst Conclusions
Guidance and consensus
Management has provided no quantitative guidance. There is no sell-side coverage and no consensus. The only forward-looking financial statement is the 20-F's assertion of sufficient liquidity for twelve months, which depends on continued funding under the July 2026 note and equity line.
Bull case
-
Validated technology with real economics: a multi-year HAECO operating record and completed Macau hospital project provide referenceable proof of ≥40% energy savings, which is a compelling value proposition for high cooling-load buildings in subtropical Asia.
-
Asset-light scale-up: SANVO's manufacturing platform could allow panel volume growth in China without the factory capex the company could never have funded, while GCDT keeps the formulation IP and design role.
-
Optionality in adjacent markets: data-center liquid cooling and cold-chain/biobank storage (with exclusive GeneHK arrangements) are structurally growing markets where even small wins would be material against a ~US$3M revenue base and ~US$5M market cap.
Bear case
-
Dilution overwhelms fundamentals: the warrant package alone (29.1M shares pre-consolidation) exceeds twice the shares outstanding, with full-ratchet and periodic reset features, convertible debt priced at a discount to recent lows, and a US$100M equity line — a classic structure that tends to transfer value from common holders to the financier.
-
Revenue cliff and concentration: with Macau completed (May 2026) and Bayview Garden substantially recognized, FY2027 revenue could revert toward the HAECO run-rate absent new lump-sum contracts; two customers were ~95% of FY2026 revenue and losses doubled to HK$13.1M even at record revenue.
-
Governance and execution capacity: a 3–4 person company with founder-owned IP, a dual-class structure giving ~98% voting control, CFO turnover post-IPO, and no granted patents is poorly equipped to execute a multi-market expansion, and minority holders have little recourse.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Q4 2026 | Post-consolidation price stability and NYSE American compliance status |
| Q4 2026 | Effectiveness of resale F-1 (triggers US$5.5M third note installment) |
| Q4 2026 – Q1 2027 | Interim results for six months to 30 Sep 2026 (6-K): revenue run-rate post-Macau, cash, debt |
| 16 Jan 2027 | July 2026 Note maturity — repayment, conversion or extension |
| ~Jan 2027 | First six-monthly warrant exercise price reset (six months after 24 Jul 2026 issuance) |
| Ongoing | Equity-line drawdowns and share count growth |
| Ongoing | Formal SANVO operating agreements; first PRC panel orders |
| Ongoing | New lump-sum or PBC contract awards; any data-center or GeneHK commercial orders |
| Ongoing | Patent grants (US/PRC) and assignment of founder-owned trademark to the company |
| Mid-2027 | FY2027 20-F (due by ~31 Jul 2027) |
Analyst verdict
Green Circle Decarbonize Technology is a genuine but sub-scale engineering business wrapped in an unattractive public-equity structure. The underlying proposition — PCM thermal storage that lets chiller plants run at peak efficiency and shift load to cheap off-peak hours — is technically sound and commercially proven at a small number of high-profile Hong Kong and Macau sites. Revenue has grown at a ~38% CAGR since FY2022 and reached HK$25.1M in FY2026. Those are the positives, and they are real.
The problems are larger. First, the growth is lumpy, contractor-style revenue: gross margins have halved since FY2022, operating losses persist at every scale, and two customers accounted for ~95% of FY2026 revenue. Second, the company emerged from its IPO having raised only US$11.5M against a pre-IPO equity deficit of HK$23.3M and borrowings of HK$31.8M; within six months it resorted to an original-issue-discount convertible note, a 29-million-share full-ratchet warrant and a US$100M equity line — instruments whose economics favour the financier over common shareholders. Third, the August 2026 dual-class recapitalization has locked in near-total founder voting control just as minority holders face heavy dilution. The share price (down ~90% from the IPO in nine months, requiring a 1-for-6 consolidation) reflects these realities.
The SANVO partnership is the most constructive development: it replaces an unfundable factory plan with an asset-light route into China. If it produces measurable panel volumes and the company converts its data-center and cold-chain pipeline into orders, the equity has optionality. Until then, the investment case rests on execution by a three-to-four person team under a financing structure that will likely keep expanding the share count.
Verdict: Speculative / high-risk. Fundamental interest only for investors able to underwrite total loss; monitor note maturity (16 Jan 2027), warrant resets, SANVO volumes and new contract awards before any constructive reassessment.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Education | Compensation (latest) |
|---|---|---|---|---|---|
Dr. Chan Kam Biu Richard | Chief Executive Officer; Executive Director; controlling shareholder | Founder 1992; MD of Boca since Jun 1995; holdco director pre-IPO | 40+ years in electrical & mechanical engineering and construction project management; Senior Project Engineer, Hutchison Whampoa Properties (1989–1995); member, Hong Kong Invention Association (2022) | Higher diploma in mechanical engineering, Hong Kong Polytechnic; master's and doctorate in business administration, Newport University | — |
Ms. Lui Lai Yuen | Chief Administrative Officer; Executive Director | From IPO effectiveness (Jan 2026) | Related-party balances with the company disclosed in 20-F XBRL | Bachelor's in business administration, La Jolla University (San Diego) | NPD |
Mr. Louis Ho Ming Leung | Chief Financial Officer | Since 8 Jun 2026 | 10+ years in accounting, financing and auditing; INED of GR Life Style Co., Future Data Group and Mabpharm; company secretary of Shanghai XNG Holdings (since May 2026); FC & company secretary, Basic House New Life Group (2019–2022); CFO, Prosperous Future Holdings (2017–2019) | Bachelor's in Quantitative Finance, Chinese University of Hong Kong; HKICPA member since 2008 | NPD |
Mr. Lai Tai Yan | Former CFO | Pre-IPO service agreement – resigned 15 Apr 2026 | No disagreement stated | NPD | NPD |
Chan Sze Man | Independent Non-Executive Director | From IPO | Named in IPO prospectus | NPD | NPD |
(Name not captured) | Independent Non-Executive Director | From IPO | Chairman of Sun Innovation Holdings (now Digital Domain Holdings, HKEX: 547) from 2003 to 2009 | NPD | NPD |
Other INED(s) | Independent Non-Executive Director(s) | From IPO | Earlier DRS (2023) named nominees Michele Takis Matsuda, Hui Ringo Wing Kun and Yuen Sau Ying Christine; final board composition at IPO could not be fully verified | NPD | NPD |
Governance Overview
| Attribute | Status |
|---|---|
Board size | Approx. 5 (2 executive + ~3 independent), not fully verified |
Controlled company | Prospectus: controlled company while Chan holds >50%; company stated it did not intend to rely on exemptions unless it ceases to be an FPI. Economic stake fell to 46.93% (Aug 2026), but voting control is now overwhelming via Class B shares |
Dual-class | Approved 10 Aug 2026: Class B = 50 votes/share; 6,360,000 Class B (pre-consolidation) held by Joyful Star (5,280,000) and Green Circle Limited (1,080,000) = 318,000,000 votes |
Implied voting control (derived) | 318,000,000 / (318,000,000 + 7,191,205 Class A votes) ≈ 97.8% |
Key-person IP dependence | Trademark and domain name owned personally by Mr. Chan and licensed to the company |
Major Shareholders
| Holder | Shares (pre-consolidation) | % of 13,551,205 outstanding (9 Aug 2026) | Notes |
|---|---|---|---|
Dr. Chan Kam Biu Richard (via Joyful Star Ltd and Green Circle Ltd) | 6,360,000 | 46.93 | Converted to Class B (50 votes) |
Wong C Ching (via Wong Tan Suen) | 360,000 | 2.66 | Founding partner subscription 2022 |
Ma Chi Heng | 240,000 | 1.77 | Founding partner subscription 2022 |
Target Capital 1, LLC | 676,205 + 1,143,962 pre-funded warrants | 4.99 (shares only) | July 2026 investor; plus 29.1M warrants and US$10M convertible note |
Public float (Class A, ex-insiders) | ≈7.19M Class A incl. above | — | StockTitan float 7.19M |
Competitive Landscape
Key Competitors
| # | Competitor | Segment overlap | Relative positioning vs GCDT |
|---|---|---|---|
| 1 | Trane Technologies (CALMAC ice storage) | Ice-based TES for chilled-water plants | Global leader in ice TES with large installed base and channel; GCDT's PCM at +8°C avoids low-temperature chillers required for ice |
| 2 | Baltimore Aircoil Company (Ice Chiller TES) | Ice TES, cooling towers | Established OEM; also a potential equipment supplier |
| 3 | EVAPCO (ice TES) | Ice TES, evaporative cooling | Established OEM |
| 4 | Carrier / CIAT (Cristopia encapsulated PCM nodules) | Encapsulated PCM/ice-ball TES | Directly analogous encapsulated-storage approach with global distribution |
| 5 | PCM Products Ltd (UK, PlusICE) | PCM formulations and encapsulation for HVAC TES | Closest product analogue; broader temperature range catalogue |
| 6 | Rubitherm Technologies (Germany) | PCM materials | Specialist PCM supplier |
| 7 | Croda (CrodaTherm bio-based PCMs) | PCM materials | Chemical major with bio-based PCM line |
| 8 | Viking Cold Solutions (US) | PCM TES for cold storage/refrigeration | Competes in cold-chain applications GCDT targets |
| 9 | Pluss Advanced Technologies (India) | PCM materials and cold-chain products | Asian PCM competitor in cold chain |
| 10 | Sunamp (UK) | PCM heat batteries for domestic heating | Competes with GCDT's planned +58°C heating product |
| 11 | Hong Kong ESCOs and E&M contractors (e.g., large building-services contractors and utility-affiliated energy services) | Building retrofit, chiller optimization, EPCs | Local incumbents with balance sheets to fund performance contracts |
| 12 | Data-center liquid/immersion cooling specialists (e.g., GRC, LiquidStack, Submer) | Immersion cooling | Far ahead in a market GCDT has only begun to design for |
Peer Comparison FY2026
| Metric | GCDT (FY2026) | PCM Products Ltd |
|---|---|---|
Revenue | HK$25.1M (~US$3.2M) | Private; NPD |
Revenue growth | +51.1% | NPD |
Gross margin | 17.3% | NPD |
Operating margin | -27.3% | NPD |
R&D intensity | NPD | NPD |



